161 related articles for article (PubMed ID: 27326258)
1. Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin.
Xin HW; Ambe CM; Miller TC; Chen JQ; Wiegand GW; Anderson AJ; Ray S; Mullinax JE; Hari DM; Koizumi T; Godbout JD; Goldsmith PK; Stojadinovic A; Rudloff U; Thorgeirsson SS; Avital I
J Cancer; 2016; 7(9):1142-51. PubMed ID: 27326258
[TBL] [Abstract][Full Text] [Related]
2. Label-retaining liver cancer cells are relatively resistant to sorafenib.
Xin HW; Ambe CM; Hari DM; Wiegand GW; Miller TC; Chen JQ; Anderson AJ; Ray S; Mullinax JE; Koizumi T; Langan RC; Burka D; Herrmann MA; Goldsmith PK; Stojadinovic A; Rudloff U; Thorgeirsson SS; Avital I
Gut; 2013 Dec; 62(12):1777-86. PubMed ID: 23411027
[TBL] [Abstract][Full Text] [Related]
3. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.
Li D; Mullinax JE; Aiken T; Xin H; Wiegand G; Anderson A; Thorgeirsson S; Avital I; Rudloff U
BMC Cancer; 2018 Jul; 18(1):772. PubMed ID: 30064387
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
[TBL] [Abstract][Full Text] [Related]
5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
8. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y
BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470
[TBL] [Abstract][Full Text] [Related]
9. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
10. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
12. Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division.
Xin HW; Hari DM; Mullinax JE; Ambe CM; Koizumi T; Ray S; Anderson AJ; Wiegand GW; Garfield SH; Thorgeirsson SS; Avital I
Stem Cells; 2012 Apr; 30(4):591-8. PubMed ID: 22331764
[TBL] [Abstract][Full Text] [Related]
13. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
Li A; Zhang R; Zhang Y; Liu X; Wang R; Liu J; Liu X; Xie Y; Cao W; Xu R; Ma Y; Cai W; Wu B; Cai S; Tang X
Am J Transl Res; 2019; 11(9):5573-5585. PubMed ID: 31632530
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
15. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.
Takao T; Masuda H; Kajitani T; Miki F; Miyazaki K; Yoshimasa Y; Katakura S; Tomisato S; Uchida S; Uchida H; Tanaka M; Maruyama T
Stem Cell Res Ther; 2022 Jun; 13(1):225. PubMed ID: 35659728
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma.
Yang X; Xia W; Chen L; Wu CX; Zhang CC; Olson P; Wang XQ
Oncotarget; 2018 Oct; 9(79):34996-35007. PubMed ID: 30405889
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
20. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Ling S; Song L; Fan N; Feng T; Liu L; Yang X; Wang M; Li Y; Tian Y; Zhao F; Liu Y; Huang Q; Hou Z; Xu F; Shi L; Li Y
Int J Oncol; 2017 Jan; 50(1):297-309. PubMed ID: 27959383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
